viewNetscientific PLC

Netscientific associate Vortex Biosciences makes first commercial sale

VTX-1 is a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs) for analysis

picture of blood
VTX-1 is a fully automated benchtop system for collecting Circulating Tumour Cells

Vortex BioSciences, a portfolio company of AIM-listed IP firm NetScientific PLC(LON:NSCI), has made the first direct commercial sale of its VTX-1 Liquid Biopsy System.

VTX-1 is a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs) for analysis.

READ: NetScientific’s Glycotest subsidiary allowed Chinese patent for liver cancer blood test

The process traps unlabelled CTCs in microscale vortices from whole blood, allowing researchers to better understand cancer progression.

Francois Martelet, Vortex BioSciences’s chairman and NetScientific’s chief executive, said it was an important step towards commercialising VTX.

The system combines industry-leading purity and high CTC capture rates of between 65%-75%, which we believe can give researchers the opportunity to open new windows into our understanding of cancer. 

READ: NetScientific investee company's technology showcased in prestigious academic journal

Gene Walther, Vortex’s chief executive, added: "The reaction to the VTX-1 throughout the marketplace has been unbelievably positive, confirming both the tremendous potential CTCs offer and the unique value of the VTX-1."

Quick facts: Netscientific PLC

Price: 8.099 GBX

Market: AIM
Market Cap: £6.36 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...



Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read